**Supplementary material**

**Supplementary Table 1.** Overall survival in patients initiating a line of treatment in 2008–2013, by ISS stage at diagnosis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | *First treatment line* | *Second treatment line* | *Third treatment line* | *Fourth treatment line* |
|  | *N* | *Median OS, months (95% CI)* | *N* | *Median OS, months(95% CI)* | *N* | *Median OS, months(95% CI)* | *N* | *Median OS, months(95% CI)* |
| *ISS stage at diagnosis* |  |  |  |  |  |  |  |  |
| I | 217 | 62.2 (51.7–NR) | 130 | 30.7 (24.1–40.1) | 58 | 16.7 (16.7–27.4) | 25 | 17.3 (7.7–22.3) |
| II | 227 | 37.5 (33.3–46.1) | 150 | 17.7 (15.6–22.5) | 71 | 12.5 (7.6–15.9) | 34 | 7.0 (2.3–19.5) |
| III | 236 | 30.3 (22.8–36.8) | 144 | 14.8 (10.9–18.8) | 71 | 10.9 (6.9–16.6) | 34 | 5.2 (2.3–9.5) |
| Missing | 237 | 30.3 (21.1–35.5) | 159 | 19.9 (16.7–24.8) | 83 | 17.0 (8.4–23.0) | 46 | 9.8 (6.1–16.5) |

Abbreviations: CI, confidence interval; ISS, International Staging System; NR, not reached; OS, overall survival.

**Supplementary Table 2.** Progression-free survival in patients initiating a line of treatment in 2008–2013, by ISS stage at diagnosis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | *First treatment line* | *Second treatment line* | *Third treatment line* | *Fourth treatment line* |
|  | *N* | *Median PFS, months (95% CI)* | *N* | *Median PFS, months(95% CI)* | *N* | *Median PFS, months(95% CI)* | *N* | *Median PFS, months(95% CI)* |
| *ISS stage at diagnosis* |  |
| I | 217 | 22.0 (20.1–26.2) | 130 | 12.3 (8.9–14.4) | 58 | 6.4 (5.5–8.7) | 25 | 5.6 (3.8–7.8) |
| II | 227 | 19.0 (17.6–20.8) | 150 | 8.8 (7.0–10.6) | 71 | 6.1 (3.8–7.3) | 34 | 3.8 (2.3–8.0) |
| III | 236 | 13.0 (10.5–17.2) | 144 | 7.2 (5.7–9.0) | 71 | 5.8 (4.0–8.2) | 33 | 3.5 (2.0–5.0) |
| Missing | 237 | 13.6 (11.8–16.6) | 159 | 9.0 (7.6–10.5) | 83 | 7.2 (4.4–9.6) | 46 | 5.8 (3.5–8.1) |

Abbreviations: CI, confidence interval; ISS, International Staging System; PFS, progression-free survival.